Clinical trial
A Non-interventional, Non-controlled, Post-marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-life OTC Setting
NCT00480194 is registered in ClinicalTrials.gov with Nycomed as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional, Non-controlled, Post-marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-life OTC Setting
- Lead sponsor
- Nycomed
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 31, 2006
- Completion date
- January 31, 2008
- Enrollment
- 1,000 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.